INVESTOR PRESENTATION March 2026 Forward Looking Statements This presentation contains certain forward-looking statements, including without limitation, statements concerning the Company's operations, economic performance and financial condition. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are developed by combining currently available information with the Company's beliefs and assumption ...

Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding the potential health benefits and risks and projected development timeline of MOLBREEVI; the timing of regulatory submissions; the potential for ...

Investor Presentation March 2026 SAFE HARBOR STATEMENT This presentation contains highly confidential and proprietary information regarding Innovative Solutions & Support, Inc. (Nasdaq: ISSC) dba Innovative Aerosystems and its subsidiaries ("IA or the "Company") and their strategy and organization. This confidential presentation is provided to you on the condition that you agree that you will hold it in strict confidence and not reproduce, disclose, forward or distribute it to any third party in whole or in ...

1 Medicines for the Brain Corporate Presentation March 2026 NASDAQ: CRVO Forward-Looking Statements This presentation includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the CervoMed Inc. (Company), including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic eff ...

OWENS CORNING Q1 2026 INVESTOR PRESENTATION This presentation shared at the following events: | 03/11/26 | IR Roadshow Hosted by Deutsche Bank – Baltimore | | --- | --- | | | Brian Chambers, Chair & Chief Executive Officer | | 03/05/26 | Wolfe Research Housing Conference – New York | | | Todd Fister, Chief Financial Officer | | 03/04/26 | Evercore ISI Housing and Building Products Symposium – New York | | | Todd Fister, Chief Financial Officer | TM FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES This prese ...

Barinthus Biotherapeutics Corporate Presentation Guiding the Immune System to Cure Disease March 2026 Nasdaq: BRNS Disclosure Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Clywedog and Barinthus Bio, in light of h ...

Fourth Quarter 2025 Financial Results March 13, 2026 1 Trademark of Trinseo PLC or its affiliates Disclosure Rules Disclosure Rules This presentation may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, forecasts, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts. Forward-looking statements may be identified by the use of words like "expect," "an ...

Accelerating the energy transition INVESTOR PRESENTATION March 2026 TSX: GRN | FSE: 52G | OTC: GRNWF TSX: GRN / FSE: 52G / OTC: GRNWF Important Disclosures Available Information Greenlane Renewables Inc. (the "Company") is a public company which is traded on the TSX (TSX: GRN), with its principal office in Vancouver, British Columbia, Canada. This Presentation is for informational purposes and is not an offer to sell or a solicitation of an offer to buy any securities in the Company and may not be relied up ...

1 Disclaimer General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment without notice. None of Abacus Global Management, Inc. (the "Company", "Abacus", Abacus Global Management", "we", "our", or "us") or its affiliates has authorized anyone to provide interested parties with additional or different information. The information contained herein does not purport to be all incl ...

Earnings Supplement Q4 and Full Year 2025 Fourth Quarter and Full Year 2025 Financial Highlights Q4 2025 Q4 2024 Revenue $19.3 million $(56.9) million Adj. EBITDA1 $2.8 million $(75.9) million Total Certs 19,308 26,065 2025 2024 Revenue $93.2 million $24.0 million Adj. EBITDA1 $15.6 million $(55.0) million Total Certs 97,348 110,652 Quarterly Results Annual Results (1) See reconciliation of GAAP to non-GAAP financial measures on slide 9. 2 Loan Origination Performance by Quarter & Channel 21,078 22,038 21,8 ...